NALCN Promoter Methylation as a Biomarker for Metastatic Risk in a Cohort of Non-Small Cell Lung Cancer Patients
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Epigenetic silencing of NALCN, a tumor suppressor, via promoter hypermethylation is linked to worse outcomes in non-small cell lung cancer (NSCLC). This NALCN methylation in circulating tumor DNA (ctDNA) may predict metastasis.
Area Of Science
- Oncology
- Molecular Biology
- Epigenetics
Background
- Liquid biopsy analyzes circulating tumor DNA (ctDNA) and cells (CTCs) for real-time cancer monitoring.
- NALCN, a sodium leak channel, functions as a tumor suppressor and is implicated in cancer progression and immunity.
- NALCN deletion correlates with increased metastasis and CTCs in peripheral blood.
Purpose Of The Study
- To investigate NALCN promoter methylation in non-small cell lung cancer (NSCLC) cell lines, tissues, and ctDNA.
- To assess the relationship between NALCN methylation, expression, and clinical outcomes in NSCLC patients.
- To evaluate NALCN methylation in ctDNA as a potential biomarker for metastasis.
Main Methods
- Real-time methylation-specific PCR (MSP) was developed and used to analyze NALCN promoter methylation.
- NALCN expression was quantified via mRNA levels in NSCLC tissues.
- NALCN methylation was assessed in Aza-treated cell lines, paired NSCLC tissues, and ctDNA from NSCLC patients and healthy donors.
Main Results
- NALCN was underexpressed in 54.5% of NSCLC tumor tissues, with higher expression in recurrence-free patients.
- NALCN promoter hypermethylation was associated with worse disease-free intervals (DFIs) in NSCLC patients.
- NALCN methylation was detected in ctDNA from 5.1% of early-stage and 10.2% of advanced NSCLC cases.
Conclusions
- Epigenetic inactivation of NALCN through promoter hypermethylation may predict metastasis in NSCLC.
- NALCN promoter methylation in ctDNA shows potential as a prognostic biomarker for NSCLC.
- Further validation in larger cohorts is needed to confirm NALCN methylation as a biomarker for metastasis and prognosis.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
In most mammals, females have two X chromosomes (XX) while males have an X and a Y chromosome (XY). The X chromosome contains significantly more genes than the Y chromosome. Therefore, to prevent an excess of X chromosome-linked gene expression in females, one of the two X chromosomes is randomly silenced during early development....